The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

It has other candidates in its late-stage obesity pipeline, headed by CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide with semaglutide. Phase 3 results reported ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Medscape Medical News, June 29, 2023 ADA 2023 Cagrilintide With Semaglutide: A Way to Prevent Diabesity? CagriSema (cagrilintide plus semaglutide) led to weight loss 'of a magnitude not previously ...